AZD9829

PreclinicalSmall molecule

AstraZeneca

AZD9829 is one of 6 small molecule programs targeting Hematological Malignancies. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Hematological MalignanciesCompleted

Hematological MalignanciesPreclinical

Completed

Competition

Competitive Landscape

6 competitors in Hematological Malignancies

#DrugCompanyPhaseTrials

TALVEY

Johnson & Johnson

Phase 2

2 2

Tecvayli

Johnson & Johnson

Phase 2

2 3

Omidubicel

NNational Heart, Lung, and Blood Institute (NHLBI)

Phase 3

1 4

Xospata

Astellas

Preclinical

1 5

Combination Drug

Bayer

Preclinical

1 6

AZD9829

AstraZeneca

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Hematological Malignancies1 trial

A Modular Phase I/II, Open-label, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Antitumor Activity of AZD9829 as Monotherapy or in Combination in Patients With CD123-Positive Hematological Malignancies

Completed· AstraZeneca logo

AstraZeneca·Preclinical·NCT06179511·56 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for AZD9829. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — AZD9829 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for AZD9829. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — AstraZeneca company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: AstraZeneca

AZD9829

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Hematological Malignancies1 trial

References

Drug Info

Quick Facts

Related News